FDA Brief

Warning letters Drugs

FDA warning letter to

EvoLife Wellness

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.

What happened

FDA reviewed the company's website, evolifewellness.com, in August 2025 and found it offers compounded semaglutide and tirzepatide drug products. The site claimed these products were "FDA-Approved" and "Clinically Proven," even though compounded drugs are not FDA-approved. FDA says those claims are false or misleading, so the products are misbranded and shipping them across state lines is a prohibited act.

What FDA found

  1. The website called the compounded drugs "FDA-Approved" when compounded drugs are not FDA-approved, so the labeling is false or misleading.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. Advertising for a compounded drug that is false or misleading in any way misbrands that drug.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. The company introduced or delivered these misbranded drugs into interstate commerce, which is a prohibited act.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. Receiving misbranded drugs in interstate commerce, or delivering them, is also a prohibited act.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells the company to immediately stop using the misleading "FDA-Approved" language and, within 15 working days, send a written response to CDER's Office of Compounding Quality and Compliance describing the steps taken, how repeat violations will be prevented, and supporting documents.

Who should pay attention

  • telehealth companies and online pharmacies selling compounded semaglutide or tirzepatide
  • compounding pharmacies whose products are marketed by partner clinics
  • marketing and compliance staff who write website copy for drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low